- Home
- ATHA vs CPHC Comparison
ATHA vs CPHC Comparison
Compare ATHA & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- CPHC
- Stock Information
- Founded
- ATHA 2011
- CPHC 1994
- Country
- ATHA United States
- CPHC United States
- Employees
- ATHA N/A
- CPHC N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- CPHC Services-Misc. Amusement & Recreation
- Sector
- ATHA Health Care
- CPHC Consumer Discretionary
- Exchange
- ATHA Nasdaq
- CPHC Nasdaq
- Market Cap
- ATHA 93.5M
- CPHC 94.6M
- IPO Year
- ATHA 2020
- CPHC 1994
- Fundamental
- Price
- ATHA $0.67
- CPHC $20.79
- Analyst Decision
- ATHA Buy
- CPHC
- Analyst Count
- ATHA 4
- CPHC 0
- Target Price
- ATHA $11.25
- CPHC N/A
- AVG Volume (30 Days)
- ATHA 14.2M
- CPHC 3.8K
- Earning Date
- ATHA 11-07-2024
- CPHC 11-07-2024
- Dividend Yield
- ATHA N/A
- CPHC 1.44%
- EPS Growth
- ATHA N/A
- CPHC N/A
- EPS
- ATHA N/A
- CPHC 0.94
- Revenue
- ATHA N/A
- CPHC $62,111,814.00
- Revenue This Year
- ATHA N/A
- CPHC N/A
- Revenue Next Year
- ATHA N/A
- CPHC N/A
- P/E Ratio
- ATHA N/A
- CPHC $20.71
- Revenue Growth
- ATHA N/A
- CPHC 0.13
- 52 Week Low
- ATHA $0.41
- CPHC $14.27
- 52 Week High
- ATHA $4.30
- CPHC $30.25
- Technical
- Relative Strength Index (RSI)
- ATHA 51.78
- CPHC 64.82
- Support Level
- ATHA $0.60
- CPHC $19.03
- Resistance Level
- ATHA $0.83
- CPHC $20.18
- Average True Range (ATR)
- ATHA 0.10
- CPHC 0.50
- MACD
- ATHA 0.03
- CPHC 0.17
- Stochastic Oscillator
- ATHA 61.60
- CPHC 100.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.